Drug intelligence / Profile preview

vonoprazan fumarate + amoxicillin + doxycycline

Development stage: Preclinical
Lead developer: Phathom Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

A triple therapy combination for the treatment of Helicobacter pylori infection. This regimen combines vonoprazan fumarate, a potassium-competitive acid blocker (PCAB) that provides potent and sustained gastric acid suppression, with two antibiotics: amoxicillin (a beta-lactam antibiotic) and doxycycline (a tetracycline antibiotic). The combination works by reducing stomach acid production while simultaneously targeting and eliminating H. pylori bacteria through dual antibiotic action.

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)PBP (Penicillin-binding protein family)Bacterial Ribosome

Beyond the preview

Go deeper on vonoprazan fumarate + amoxicillin + doxycycline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on vonoprazan fumarate + amoxicillin + doxycycline.

Explore the full profile